FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition, in vitro studies indicate that loxapine and 8-OH loxapine are not inhibitors of UGT1A1, 1A3, 1A4, 2B7 and 2B15.
Slovenian: Poleg tega študije in vitro nakazujejo, da loksapin in 8-OH-loksapin ne inhibirata UGT1A1, 1A3, 1A4, 2B7 in 2B15.
English: In studies in agitated patients, bronchospasm was reported as an uncommon, but serious adverse reaction, while in subjects with active airways disease, bronchospasm was commonly reported and often required treatment with a short-acting beta-agonist bronchodilator.
Slovenian: V študijah z agitiranimi bolniki so o bronhospazmu poročali kot o občasnem, a resnem neželenem učinku, medtem ko so pri bolnikih z aktivno boleznijo dihalnih poti o bronhospazmu pogosto poročali in je ta večkrat zahteval zdravljenje s kratkotrajno delujočim bronhodilatatorjem tipa agonistov betaadrenergičnih receptorjev.
English: Firmly pull the plastic tab from the rear of the inhaler.
Slovenian: Močno potegnite plastični jeziček z zadnjega konca inhalatorja.
English: NOTE: If the green light stays on after the patient inhales, instruct the patient to repeat steps 3-5.
Slovenian: OPOMBA: Če zelena lučka po vdihu še vedno gori, bolniku svetujte, naj ponovi korake 3−5.
English: The most commonly reported adverse reactions during treatment with ADASUVE were dysgeusia, sedation/somnolence and dizziness (dizziness was more common after placebo treatment than loxapine treatment).
Slovenian: Najpogostejši neželeni učinki, o katerih so poročali med zdravljenjem z zdravilom ADASUVE, so bili disgevzija, sedacija/zaspanost in omotičnost (omotičnost je bila pogostejša po zdravljenju s placebom kot po zdravljenju z loksapinom).
English: Additional side effects which have been related to long term use of loxapine by mouth and which may be relevant for ADASUVE include faintness upon standing, increased heart rate, increased blood pressure, blurred vision, dry eyes, and decreased urination.
Slovenian: Dodatni neželeni učinki, ki so bili povezani z dolgotrajno peroralno uporabo loksapina in ki so lahko pomembni za zdravilo ADASUVE, vključujejo vrtoglavico ob vstajanju, povišano srčno frekvenco, povišan krvni tlak, zamegljen vid, suhe oči in zmanjšano uriniranje.
English: • have or had heart problems or stroke
Slovenian: • imate ali ste imeli težave s srcem ali ste doživeli srčno kap;
English: For complete instructions on how to use ADASUVE see information for the healthcare professional section of the package leaflet.
Slovenian: Za celotna navodila o uporabi zdravila ADASUVE glejte informacije v poglavju za zdravstvenega delavca v navodilu za uporabo.
English: Loxapine is a substrate for several CYP450 isozymes; in vitro studies demonstrated that 7-OHloxapine is formed mainly by CYPs 3A4 and 2D6, 8-OH-loxapine is formed mainly by CYP1A2, amoxapine is formed mainly by CYP3A4, 2C19, and 2C8, and loxapine N-oxide is formed by FMOs.
Slovenian: Loksapin je substrat za številne izocime CYP450; študije in vitro so pokazale, da se 7-OH-loksapin tvori predvsem s CYP-ji 3A4 in 2D6, 8-OH-loksapin se tvori predvsem s CYP1A2, amoksapin se tvori predvsem s CYP3A4, 2C19 in 2C8, loksapin N-okside pa se tvori s FMO-ji.
English: ADASUVE has not been studied in elderly patients, including those with dementia-related psychosis.
Slovenian: Zdravilo ADASUVE ni bilo preučeno pri starejših bolnikih, vključno s tistimi, ki imajo psihozo, povezano z demenco.
English: • ADASUVE may cause narrowing of the airways (bronchospasm) and may cause you to wheeze, cough, feel chest tightness or have shortness of breath.
Slovenian: • Zdravilo ADASUVE lahko povzroči zoženje dihalnih poti (bronhospazem) ter povzroči sopenje, kašelj, občutek tiščanja v prsnem košu ali kratko sapo.
English: Potential for ADASUVE to affect other medicinal products
Slovenian: Morebiten vpliv zdravila ADASUVE na delovanje drugih zdravil
English: Co-administration of loxapine and adrenaline may cause worsening of hypotension (see section 4.4).
Slovenian: Sočasno dajanje loksapina in adrenalina lahko povzroči poslabšanje hipotenzije (glejte poglavje 4.4).
English: Uncommon: bronchospasm (including shortness of breath) Gastrointestinal disorders
Slovenian: Občasni: bronhospazem (vključno s kratko sapo) Bolezni prebavil
English: Treatment with ADASUVE may have to be stopped if this occurs.
Slovenian: V tem primeru bo morda treba prekiniti zdravljenje z zdravilom ADASUVE.
English: ADASUVE is for inhalation use.
Slovenian: Zdravilo ADASUVE je namenjeno za uporabo z inhaliranjem.
English: • have or had breathing problems like asthma or other chronic lung diseases such as bronchitis or emphysema
Slovenian: • imate ali ste imeli težave z dihanjem, kot so astma ali druge kronične pljučne bolezni, npr.
English: Potential for other medicinal products to affect ADASUVE
Slovenian: Morebiten vpliv drugih zdravil na delovanje zdravila ADASUVE
English: The main metabolic pathways include hydroxylation to form 8-OH-loxapine and 7-OH-loxapine, N-oxidation to form loxapine N-oxide, and de-methylation to form amoxapine.
Slovenian: Glavne presnovne poti vključujejo hidroksilacijo za tvorjenje 8-OH-loksapina in 7-OH-loksapina, N-oksidacijo za tvorjenje loksapin N-oksida in demetilacijo za tvorbo amoksapina.
English: • already used ADASUVE and you developed symptoms of wheezing or shortness of breath
Slovenian: • ste že uporabljali zdravilo ADASUVE in ste opazili simptome sopenja ali kratke sape;
English: • Summary of Product Characteristics (SmPC) and Package Leaflet and Labelling • Educational material for the healthcare professionals
Slovenian: • povzetek glavnih značilnosti zdravila (SmPC), navodila za uporabo in označevanje,
English: For ADASUVE, the order of metabolites observed in humans (based on systemic exposure) was 8-OH-loxapine >> loxapine N oxide > 7-OH-loxapine > amoxapine, with plasma levels of 8-OH-loxapine similar to the parent compound.
Slovenian: Za zdravilo ADASUVE je bilo zaporedje metabolitov, ki so jih opazovali pri ljudeh (na podlagi sistemske izpostavljenosti) 8-OH-loksapin >> loksapin N oksid > 7-OH-loksapin > amoksapin, pri čemer so ravni 8-OH-loksapina v plazmi podobne matični spojini.
English: The European Medicines Agency has waived the obligation to submit the results of studies with ADASUVE in the subset of the paediatric population from birth to less than 12 years of age for the treatment of schizophrenia and in the subset from birth to less than 10 years of age for the treatment of bipolar disorder (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom ADASUVE za podskupino pediatrične populacije od rojstva do manj kot 12. leta starosti za zdravljenje shizofrenije in za podskupino od rojstva do manj kot 10. leta starosti za zdravljenje bipolarne motnje (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Do not use ADASUVE
Slovenian: Ne uporabljajte zdravila ADASUVE:
English: Loxapine is removed rapidly from the plasma and distributed in tissues.
Slovenian: Loksapin se hitro odstrani iz plazme in porazdeli v tkiva.
English: Decreased agitation was evident 10 minutes after Dose 1, the first assessment time, and at all subsequent assessments during the 24 hour evaluation period, for both 4.5 mg and 9.1 mg doses in both schizophrenia and bipolar disorder patients.
Slovenian: Zmanjšana agitiranost je bila očitna 10 minut po prvem odmerku, ob prvem ocenjevanju, ter ob vseh nadaljnjih ocenjevanjih v 24-urnem ocenjevalnem obdobju, tako za odmerek 4,5 mg kot za odmerek 9,1 mg pri bolnikih s shizofrenijo in pri bolnikih z bipolarno motnjo.
English: The potential for loxapine and its metabolites (amoxapine, 7-OH-loxapine, 8-OH-loxapine, and loxapine-N-oxide) to inhibit CYP450 - mediated drug metabolism has been examined in vitro for CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4.
Slovenian: Vpliv loksapina in njegovih presnovkov (amoksapina, 7-OH-loksapina, 8-OH-loksapina in loksapin N-oksida) na zaviranje presnove zdravila preko CYP450 je bil preučen in vitro za CYP 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 in 3A4.
English: Patients should be advised not to breast feed for a period of 48 hours after receiving loxapine and discard the milk produced in the meantime.
Slovenian: Bolnicam je treba odsvetovati dojenje v obdobju 48 ur po prejemu loksapina in da zavržejo mleko, ki nastane v tem času.
English: Renal and/or hepatic impairment ADASUVE has not been studied in patients with renal or hepatic impairment.
Slovenian: Ledvična in/ali jetrna okvara Zdravilo ADASUVE ni bilo preučeno pri bolnikih z ledvično ali jetrno okvaro.
English: Assessment of adverse reactions from clinical study data is based on two Phase 3 and one Phase 2A short-term (24-hour) placebo-controlled clinical trials enrolling 524 adult patients with agitation associated with schizophrenia (including 27 patients with schizoaffective disorder) or bipolar disorder, treated with ADASUVE 4.5 mg (265 patients) or ADASUVE 9.1 mg (259 patients).
Slovenian: Ocena neželenih učinkov na podlagi podatkov klinične študije temelji na dveh kratkoročnih (24-urnih) kliničnih preskušanjih faze 3 in enega kratkoročnega kliničnega preskušanja faze 2A, ki so bila nadzorovana s placebom in so vključevala 524 odraslih bolnikov z agitiranostjo, povezano s shizofrenijo (vključno s 27 bolniki s shizoafektivno motnjo), ali z bipolarno motnjo, ki so bili zdravljeni z zdravilom ADASUVE 4,5 mg (265 bolnikov) ali z zdravilom ADASUVE 9,1 mg (259 bolnikov).
English: The following symptoms may occur in newborn babies of mothers that have repeatedly used antipsychotic medicines in the last three months of their pregnancy: shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Slovenian: Pri novorojenčkih mater, ki so večkrat uporabile antipsihotike v zadnjih treh mesecih nosečnosti, se lahko pojavijo naslednji simptomi: tresenje, okornost in/ali šibkost mišic, zaspanost, agitacija, težave z dihanjem in motnje hranjenja.
English: Upon completion of the inhalation, the patient removes the mouthpiece from mouth and holds breath briefly.
Slovenian: Po končanem inhaliranju bolnik odstrani ustnik iz ust in za kratek čas zadrži dih.
English: ADASUVE is not recommended in patient populations with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolaemia, and treatment with antihypertensive medicinal products).
Slovenian: Zdravilo ADASUVE ni priporočeno za populacije bolnikov z znano srčno-žilno boleznijo (anamneza miokardnega infarkta ali ishemične bolezni srca, odpovedi srca ali motenj prevodnosti), s cerebrovaskularnim obolenjem ali s stanji, zaradi katerih so bolniki nagnjeni k hipotenziji (dehidracija, hipovolemija in zdravljenje z antihipertenzivnimi zdravili).
English: When it occurred, it was typically reported within 25 minutes after dosing.
Slovenian: Kadar je prišlo do bronhospazma, so običajno poročali, da se je pojavil v 25 minutah po odmerjanju.
English: New-born infants exposed repeatedly to antipsychotics during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Slovenian: Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti večkrat izpostavljeni antipsihotikom, obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih izraženost in čas trajanja po porodu sta lahko različna.
English: Loxapine exposure in the first 2 hours after administration (AUC0-2h, a measure of early exposure that is relevant to the onset of therapeutic effect) was 25.6 ng*h/mL for the 4.5 mg dose and 66.7 ng*h/mL for the 9.1 mg dose in healthy subjects.
Slovenian: Izpostavljenost loksapinu v prvih dveh urah po dajanju (AUC0-2h, meritev zgodnje izpostavljenosti, ki je pomembna za nastop terapevtskega učinka) je bila 25,6 ng*h/mL za odmerek 4,5 mg in 66,7 ng*h/mL za odmerek 9,1 mg pri zdravih osebah.
English: In vitro studies indicate that loxapine and 8-OH-loxapine are not inducers of CYP1A2, 2B6 or 3A4 enzymes at clinically relevant concentrations.
Slovenian: Študije in vitro nakazujejo, da loksapin in 8-OH-loksapin ne inducirata encimov CYP1A2, 2B6 ali 3A4 v klinično pomembnih koncentracijah.
English: Patient should be observed during the first hour after each dose for signs and symptoms of bronchospasm.
Slovenian: Bolnika je prvo uro po vsakem odmerku treba opazovati za znake in simptome bronhospazma.
English: Patients should be observed during the first hour after each dose for signs and symptoms of bronchospasm.
Slovenian: Bolnike je prvo uro po vsakem odmerku treba opazovati za znake in simptome bronhospazma.
English: ADASUVE is not indicated for the treatment of patients with dementia-related psychosis.
Slovenian: Zdravilo ADASUVE ni indicirano za zdravljenje bolnikov s psihozo, povezano z demenco.
English: Extrapyramidal symptoms
Slovenian: Ekstrapiramidni simptomi
English: Uncommon (may affect up to 1 in 100 people): muscle or eye movements you can't control, lack of coordination, sustained muscle contraction, or feeling restless or unable to sit still.
Slovenian: Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): gibanje mišic ali očesa, ki ga ne morete nadzirati, pomanjkanje koordinacije, trajno krčenje mišic ali občutek nemira oz. nezmožnost sedeti pri miru.
English: ADASUVE has not been investigated in patients with other forms of lung disease.
Slovenian: Zdravila ADASUVE niso preučevali pri bolnikih z drugimi oblikami pljučne bolezni.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with ADASUVE in the subset of the paediatric population from 12 to less than 18 years of age for the treatment of schizophrenia and in the subset from 10 years to less than 18 years of age in bipolar disorder (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom ADASUVE za podskupino pediatrične populacije od 12. leta do manj kot 18. leta starosti za zdravljenje shizofrenije in za podskupino od 10. leta do manj kot 18. leta starosti za zdravljenje bipolarne motnje (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Each inhaler is provided in a sealed, multilaminate aluminum foil pouch.
Slovenian: Vsak inhalator je dobavljen v zapečateni večplastni vrečki iz aluminijeve folije.
English: If signs and symptoms of tardive dyskinesia appear in a patient being treated with loxapine, discontinuation should be considered.
Slovenian: Če se pri bolniku, ki je zdravljen z loksapinom, pojavijo znaki in simptomi tardivne diskinezije, je treba razmisliti o prekinitvi zdravljenja.
English: Hold the inhaler away from the mouth and breathe out fully to empty lungs.
Slovenian: Podržite inhalator stran od ust in izdihnite, da povsem izpraznite pljuča.
English: The pharmacokinetic parameters of loxapine were determined in subjects on chronic, stable antipsychotic regimens following repeat administration of ADASUVE every 4 hours for a total of 3 doses (either 4.5 mg or 9.1 mg).
Slovenian: Farmakokinetični parametri loksapina so bili določeni pri bolnikih z dolgotrajnimi, stabilnimi shemami zdravljenja z antipsihotiki po večkratnem dajanju zdravila ADASUVE vsake 4 ure za skupno 3 odmerke (bodisi 4,5 mg ali 9,1 mg).
English: The mean plasma loxapine concentrations following administration of ADASUVE were linear over the clinical dose range.
Slovenian: Povprečne plazemske koncentracije loksapina po dajanju zdravila ADASUVE so bile linearne v kliničnem odmernem območju.
English: Patients were randomised to placebo, ADASUVE 4.5 mg and ADASUVE 9.1 mg.
Slovenian: Bolniki so bili randomizirani v skupino s placebom, skupino z zdravilom ADASUVE 4,5 mg in skupino z zdravilom ADASUVE 9,1 mg.
English: Because of anticholinergic action, ADASUVE should be used cautiously in patients with glaucoma or a tendency to urinary retention, particularly with concomitant administration of anticholinergic-type antiparkinson medicinal products.
Slovenian: Zaradi antiholinergičnega delovanja je treba zdravilo ADASUVE uporabljati previdno pri bolnikih z glavkomom ali z nagnjenostjo k zadrževanju urina, še posebej, če sočasno jemljejo zdravila za zdravljenje Parkinsonove bolezni z antiholinergičnim delovanjem.
English: Loxapine may cause severe respiratory depression if combined with other CNS-depressants (see section 4.4).
Slovenian: Loksapin lahko povzroči hudo respiratorno depresijo, če je kombiniran z drugimi sredstvi za depresijo osrednjega živčevja (glejte poglavje 4.4).
English: Uncommon: hypotension
Slovenian: Občasni: hipotenzija
English: Given the primary CNS effects of loxapine, ADASUVE should be used with caution in combination with alcohol or other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc.
Slovenian: Glede na primarne učinke loksapina na osrednje živčevje je pri uporabi zdravila ADASUVE potrebna previdnost v kombinacijah z alkoholom ali z drugimi zdravili, ki delujejo na osrednje živčevje, npr. anksiolitiki, večina antipsihotikov, hipnotiki, opiati itd.
English: If vasopressor therapy is required, noradrenaline or phenylephrine is preferred.
Slovenian: Če je potrebno zdravljenje z vazopresorji, sta priporočljiva noradrenalin ali fenilefrin.
English: No data are available on the use of ADASUVE in patients with underlying cardiovascular diseases.
Slovenian: V zvezi z uporabo zdravila ADASUVE pri bolnikih z obstoječimi srčno-žilnimi boleznimi ni podatkov.
English: If you are concerned that you are given more ADASUVE than you feel necessary, tell your doctor or nurse of your concern.
Slovenian: Če vas skrbi, da ste prejeli večji odmerek zdravila ADASUVE, kot bi smeli, o tem obvestite zdravnika ali medicinsko sestro.
English: How to store ADASUVE 6.
Slovenian: Shranjevanje zdravila ADASUVE 6.
English: Non-clinical safety data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, and genotoxicity, except for changes to reproductive tissues related to the extended pharmacology of loxapine.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih in genotoksičnosti so pokazali, da ne obstaja posebno tveganje za človeka z izjemo sprememb v reproduktivnih tkivih, ki so povezane z razširjeno farmakologijo loksapina.
English: Given the primary Central Nervous System (CNS) effects of loxapine, ADASUVE should be used with caution in patients with compromised respiration, such as hypovigilant patients or patients with CNS-depression due to alcohol or other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc. (see section 4.5).
Slovenian: Glede na primarne učinke loksapina na osrednje živčevje je pri uporabi zdravila ADASUVE potrebna previdnost pri bolnikih z oslabljenim dihanjem, kot so na primer hipovigilantni bolniki ali bolniki z depresijo osrednjega živčevja zaradi alkohola ali zaradi drugih zdravil, ki delujejo na osrednje živčevje, npr. anksiolitiki, večina antipsihotikov, hipnotiki, opiati itd. (glejte poglavje 4.5).
English: Loxapine should be used with caution in patients with a history of convulsive disorders since it lowers the convulsive threshold.
Slovenian: Loksapin je treba uporabljati previdno pri bolnikih z anamnezo epizod napadov, saj znižuje prag za epileptični napad.
English: Change at 2 hr post dose
Slovenian: Sprememba v 2 urah po odmerku
English: How to use ADASUVE
Slovenian: Kako uporabljati zdravilo ADASUVE
English: Do not use ADASUVE again if NMS occurs.
Slovenian: Če je prišlo do NMS, zdravila ADASUVE ne uporabite znova.
English: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Slovenian: Klinično izraženi znaki nevroleptičnega malignega sindroma so hiperpireksija, mišična rigidnost, spremenjeno duševno stanje in znamenja avtonomne labilnosti (nereden srčni utrip ali krvni tlak, tahikardija, čezmerno znojenje in motnje srčnega ritma).
English: The recommended initial dose of ADASUVE is 9.1 mg. As this dose cannot be reach with this presentation (ADASUVE 4.5 mg), the presentation ADASUVE 9.1 mg should be used initially.
Slovenian: Ker tega odmerka ni mogoče doseči s to jakostjo zdravila (ADASUVE 4,5 mg), je potrebno na začetku uporabiti zdravilo ADASUVE 9,1 mg.
English: Common (may affect up to 1 in 10 people): dizziness, throat irritation, dry mouth or tiredness.
Slovenian: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): omotičnost, draženje žrela, suha usta ali utrujenost.
English: Tear open the foil pouch and remove the inhaler from the package.
Slovenian: Pretrgajte vrečko iz folije in vzemite inhalator iz pakiranja.
English: ADASUVE is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
Slovenian: Zdravilo ADASUVE je indicirano za hitro obvladanje blage do zmerne agitacije pri odraslih bolnikih s shizofrenijo ali bipolarno motnjo.
English: No cases of overdosage of ADASUVE were reported in clinical studies.
Slovenian: V kliničnih študijah niso poročali o primerih prevelikega odmerjanja zdravila ADASUVE.
English: The product is packaged in a sealed pouch.
Slovenian: Zdravilo je pakirano v zatesnjeno vrečko.
English: ADASUVE is used to treat acute symptoms of mild-to-moderate agitation that may occur in adult patients who have schizophrenia or bipolar disorder.
Slovenian: Zdravilo ADASUVE uporabljamo za zdravljenje simptomov blage do zmerne agitacije, ki se lahko pojavijo pri odraslih bolnikih s shizofrenijo ali bipolarno motnjo.
English: Loxapine is not expected to cause clinically important pharmacokinetic interactions with medicinal products that are either metabolised by cytochrome P450 (CYP450) isozymes or glucuronidated by human uridine 5'-diphosphoglucuronosyl transferases (UGTs) .
Slovenian: Ni pričakovati klinično pomembnih farmakokinetičnih medsebojnih delovanj loksapina z zdravili, ki jih bodisi presnavljajo izocimi citokroma P450 (CYP450) ali pa jih gluguronidira humana 5'difosfoglukuronozil transferaza (UGTs).
English: Caution is advised if loxapine is combined with other medicinal products known to lower the seizure threshold, e.g. phenothiazines or butyrophenones, clozapine, tricyclics or selective serotonine reuptake inhibitors (SSRIs), tramadol, mefloquine (see section 4.4).
Slovenian: Potrebna je previdnost, če je loksapin kombiniran z drugimi zdravili, za katera je znano, da znižujejo prag za epileptične napade, npr. fenotiazini ali butirofenoni, klozapin, triciklični antidepresivi ali selektivni zaviralci ponovnega privzema serotonina (SSRI-ji), tramadol, meflokin (glejte poglavje
English: • Caution to be exercised when ADASUVE is administered in patients with known cardiovascular disease or a family history of QT prolongation, and in cases of concomitant use with other medicial products known to prolong the QT interval
Slovenian: • Previdnost je potrebna, kadar zdravilo ADASUVE dajemo bolnikom z znano srčno-žilno boleznijo ali z družinsko anamnezo podaljšanja intervala QT ter v primerih sočasne uporabe z drugimi zdravili, za katera je znano, da podaljšajo interval QT.
English: If your baby develops any of these symptoms you may need to contact your doctor.
Slovenian: Če pri dojenčku opazite katerega koli od teh simptomov, se posvetujte z zdravnikom.